Comparison between 1.5- and 3-T Magnetic Resonance Acquisitions for Direct Targeting Stereotactic Procedures for Deep Brain Stimulation: A Phantom Study.


Journal

Stereotactic and functional neurosurgery
ISSN: 1423-0372
Titre abrégé: Stereotact Funct Neurosurg
Pays: Switzerland
ID NLM: 8902881

Informations de publication

Date de publication:
2020
Historique:
received: 09 03 2020
accepted: 09 06 2020
pubmed: 24 8 2020
medline: 1 6 2021
entrez: 24 8 2020
Statut: ppublish

Résumé

Deep brain stimulation (DBS) is a well-established treatment for movement disorders. High magnetic fields could have an impact on distortion. We evaluated 1.5- and 3-T magnetic resonance imaging (MRI) sequences for accuracy, precision, and trueness of our MRI-guided direct targeting protocol. Effects of distortion on MR sequences (T1- and T2-weighted sequences) can be evaluated using a dedicated phantom (Elekta). Field strength capabilities were assessed on Siemens Avanto (1.5 T) and Skyra (3 T) scanners. We assessed the precision of our stereotactic MRI-guided procedure. We focused on the risk of error due to a high field strength. Error values on the localizer box were between 0.4 and 0.7 mm at 1.5 T and between 0.6 and 2 mm at 3 T. The most accurate 1.5-T sequence is the 3D FLASH T1-weighted sequence, which had an accuracy value of 0.6 mm. At 3 T, the accuracy value of the isotropic 3D FLASH T1-weighted sequence was 1.6 mm. Given the millimetric size of stereotactic targets and electrodes, lead implantation for neuromodulation therapy needs to be accurate. We demonstrate that 3-T imaging could not be used for stereotaxy in our MRI-guided direct targeting protocol because of a risk of error induced by distortion.

Identifiants

pubmed: 32829341
pii: 000509303
doi: 10.1159/000509303
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

337-344

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Gaëtan Poulen (G)

Unité "Pathologies Cérébrales Résistantes," CHU Montpellier, Montpellier, France, g-poulen@chu-montpellier.fr.
Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France, g-poulen@chu-montpellier.fr.
Université de Montpellier, Montpellier, France, g-poulen@chu-montpellier.fr.
Institut de Génomique Fonctionnelle, Montpellier, France, g-poulen@chu-montpellier.fr.
CNRS UMR5203, Montpellier, France, g-poulen@chu-montpellier.fr.
INSERM U661, Montpellier, France, g-poulen@chu-montpellier.fr.

Emilie Chan Seng (E)

Unité "Pathologies Cérébrales Résistantes," CHU Montpellier, Montpellier, France.
Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France.
Université de Montpellier, Montpellier, France.
Institut de Génomique Fonctionnelle, Montpellier, France.
CNRS UMR5203, Montpellier, France.
INSERM U661, Montpellier, France.

Nicolas Menjot De Champfleur (N)

Unité de Neuroradiologie, CHU Montpellier, Montpellier, France.

Laura Cif (L)

Unité "Pathologies Cérébrales Résistantes," CHU Montpellier, Montpellier, France.
Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France.
Université de Montpellier, Montpellier, France.
Institut de Génomique Fonctionnelle, Montpellier, France.
CNRS UMR5203, Montpellier, France.
INSERM U661, Montpellier, France.

Fabienne Cyprien (F)

Unité "Pathologies Cérébrales Résistantes," CHU Montpellier, Montpellier, France.
Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France.
Université de Montpellier, Montpellier, France.
Institut de Génomique Fonctionnelle, Montpellier, France.
CNRS UMR5203, Montpellier, France.
INSERM U661, Montpellier, France.

Jerome Perez (J)

Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France.
Université de Montpellier, Montpellier, France.
Institut de Génomique Fonctionnelle, Montpellier, France.
CNRS UMR5203, Montpellier, France.
INSERM U661, Montpellier, France.

Philippe Coubes (P)

Unité "Pathologies Cérébrales Résistantes," CHU Montpellier, Montpellier, France.
Unité de Recherche sur les Comportements et Mouvements Anormaux, CHU Montpellier, Montpellier, France.
Université de Montpellier, Montpellier, France.
Institut de Génomique Fonctionnelle, Montpellier, France.
CNRS UMR5203, Montpellier, France.
INSERM U661, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH